Abstract
Background: Phosphodiesterase-5 (PDE5) inhibitors demonstrate off-label anticancer properties, acting through a variety of mechanisms that ultimately reduce tumor proliferation.
Method: Combining PDE5 inhibitors with other anti-oncotic agents further enhances their effectiveness against tumors. Mechanistically, PDE5 inhibitors have been shown to inhibit ATP binding cassette (ABC) transporter protein activity, potentiate reactive oxygen species (ROS) activity, decrease FADD-like IL-1β-converting enzyme (FLICE)- inhibitory protein (c-FLIP) expression, increase blood-brain tumor barrier (BTB) permeability, and, when administered as a combination therapy, sensitize tumors to platinum.
Conclusion: This review offers insights into the various mechanisms by which PDE5 inhibitors exert their antineoplastic actions.
Keywords: ABC transporter, anticancer therapy, antineoplastic agents, phosphodiesterase inhibitors, reactive oxygen species, sildenafil, Viagra®.
Current Cancer Therapy Reviews
Title:PDE5 Inhibitors Offer Novel Mechanisms in Combination and Solo Cancer Therapy
Volume: 13 Issue: 2
Author(s): Robert W. Lyday , Abigail M. Etters, Chris Kim, Fernando Magana, Gabriel M. Pontipiedra, Naveen K.M. Singh and Samuel Kadavakollu *
Affiliation:
- Department of Biomedical Sciences, Burrell College of Osteopathic Medicine, Las Cruces, NM 88001,United States
Keywords: ABC transporter, anticancer therapy, antineoplastic agents, phosphodiesterase inhibitors, reactive oxygen species, sildenafil, Viagra®.
Abstract: Background: Phosphodiesterase-5 (PDE5) inhibitors demonstrate off-label anticancer properties, acting through a variety of mechanisms that ultimately reduce tumor proliferation.
Method: Combining PDE5 inhibitors with other anti-oncotic agents further enhances their effectiveness against tumors. Mechanistically, PDE5 inhibitors have been shown to inhibit ATP binding cassette (ABC) transporter protein activity, potentiate reactive oxygen species (ROS) activity, decrease FADD-like IL-1β-converting enzyme (FLICE)- inhibitory protein (c-FLIP) expression, increase blood-brain tumor barrier (BTB) permeability, and, when administered as a combination therapy, sensitize tumors to platinum.
Conclusion: This review offers insights into the various mechanisms by which PDE5 inhibitors exert their antineoplastic actions.
Export Options
About this article
Cite this article as:
Lyday W. Robert , Etters M. Abigail , Kim Chris , Magana Fernando, Pontipiedra M. Gabriel , Singh K.M. Naveen and Kadavakollu Samuel *, PDE5 Inhibitors Offer Novel Mechanisms in Combination and Solo Cancer Therapy, Current Cancer Therapy Reviews 2017; 13 (2) . https://dx.doi.org/10.2174/1573394713666170731152749
DOI https://dx.doi.org/10.2174/1573394713666170731152749 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melatonin and Hypothalamic-Pituitary-Gonadal Axis
Current Medicinal Chemistry High Podophyllotoxin Producing Hairy Root Line of Linum Album: Influence of Carbohydrates, Temperature and Photoperiod
Current Biotechnology Current Strategy for Cisplatin Delivery
Current Cancer Drug Targets A Review on Hemisynthesis, Biosynthesis, Biological Activities, Mode of Action, and Structure-Activity Relationship of Podophyllotoxins: 2003- 2007
Current Medicinal Chemistry Increased Akt Signaling Resulting from the Loss of Androgen Responsiveness in Prostate Cancer
Current Medicinal Chemistry The Effects of Weightlessness on the Human Organism and Mammalian Cells
Current Molecular Medicine Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Monofunctional Platinum (PtII) Compounds – Shifting the Paradigm in Designing New Pt-based Anticancer Agents
Current Medicinal Chemistry Carbon Nanotube-Based Electrochemical Biosensing Platforms: Fundamentals,Applications, and Future Possibilities
Recent Patents on Biotechnology Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic Pathways
Current Medicinal Chemistry - Anti-Cancer Agents A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-γ as a New Target Therapy in the Treatment of Human Urological Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections
Current Topics in Medicinal Chemistry Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics Phytoestrogen Genistein and Its Pharmacological Interactions with Synthetic Endocrine-Active Compounds
Current Pharmaceutical Design Application of Radioisotopes in Anti-Fungal Research and Fungal Disease Studies
Current Medicinal Chemistry - Anti-Infective Agents Stem Cells and Combinatorial Science
Combinatorial Chemistry & High Throughput Screening Advances in Development of Inhibitors of 17β-Hydroxysteroid Dehydrogenases
Anti-Cancer Agents in Medicinal Chemistry Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design Nature and Nurture in the Early-Life Origins of Metabolic Syndrome
Current Pharmaceutical Biotechnology Preface
Recent Patents on Anti-Cancer Drug Discovery